GP5 and cancer: In studies using the validation of human papillomavirus (HPV) genotyping tests (VALGENT) study framework, which is designed to allow test comparison and the validation of HPV assays, the Cepheid Xpert HPV test was validated for screening, as it showed comparable accuracy for cervical pre-cancer as compared to standard comparator tests, i.e. HC2 and GP5+/6+-EIA [26, 27].